

Genentech Clinical Development Pipeline

ONCOLOGY/HEMATOLOGY

Molecule	Indication	Phase I	Phase II
AKT Inhibitor (GDC-0068, RG7440)	<ul style="list-style-type: none"> Solid tumors 		
Anti-angiogenic (RG7594)	<ul style="list-style-type: none"> Solid tumors 		
Anti-CD22 Antibody Drug Conjugate (RG7593)	<ul style="list-style-type: none"> Hematologic malignancies 		
Antibody Drug Conjugate (RG7596)	<ul style="list-style-type: none"> Hematologic malignancies 		
Antibody Drug Conjugate (RG7599)	<ul style="list-style-type: none"> Non-small cell lung cancer and ovarian cancer 		
Antibody Drug Conjugate (RG7458)	<ul style="list-style-type: none"> Ovarian cancer 		
Antibody Drug Conjugate (RG7450)	<ul style="list-style-type: none"> Prostate cancer 		
Anti-EGFL7 MAb (RG7414)	<ul style="list-style-type: none"> Solid tumors Non-small cell lung cancer 		
Anti-FGFR3 MAb (RG7444)	<ul style="list-style-type: none"> Multiple Myeloma 		
Anti-HER3 EGFR DAF (RG7597)	<ul style="list-style-type: none"> Metastatic epithelial tumors 		
Bcl-2 Inhibitor (GDC-0199, RG7601)	<ul style="list-style-type: none"> Chronic lymphocytic leukemia 		
Cancer Immunotherapy (RG7446)	<ul style="list-style-type: none"> Solid tumors 		
ChK-1 Inhibitor (GDC-0425, RG7602)	<ul style="list-style-type: none"> Solid tumors or lymphoma 		
IAP Antagonist(2) (GDC-0917, RG7459)	<ul style="list-style-type: none"> Solid tumors or lymphoma 		
MEK Inhibitor (GDC-0623, RG7420)	<ul style="list-style-type: none"> Solid tumors 		
MEK Inhibitor (GDC-0973, RG7421)	<ul style="list-style-type: none"> Solid tumors Solid tumors (in combo with GDC-0941) Metastatic melanoma (in combo with vemurafenib) 		
Navitoclax, Bcl-2 Inhibitor (ABT-263, RG7423)	<ul style="list-style-type: none"> Solid tumors and hematologic malignancies Front-line chronic lymphocytic leukemia Relapsed or refractory chronic lymphocytic leukemia Relapsed or refractory lymphoid malignancies 		
PI3 Kinase Inhibitor (GDC-0941, RG7321)	<ul style="list-style-type: none"> Solid tumors or non-Hodgkin's lymphoma 1L HER2- metastatic breast cancer 2L HER2+ metastatic breast cancer Metastatic non-small cell lung cancer 		
PI3 Kinase Inhibitor (GDC-0032, RG7604)	<ul style="list-style-type: none"> Solid tumors 		
PI3K/mTOR Dual Inhibitor (GDC-0980, RG7422)	<ul style="list-style-type: none"> Solid tumors or non-Hodgkin's lymphoma Metastatic breast cancer 		
Small Molecule (GDC-0349, RG7603)	<ul style="list-style-type: none"> Solid tumors or non-Hodgkin's lymphoma 		

IMMUNOLOGY

Molecule	Indication	Phase I	Phase II
Anti-LT α (RG7416)	<ul style="list-style-type: none"> Rheumatoid arthritis 		
Anti-M1 prime (RG7449)	<ul style="list-style-type: none"> Asthma 		
rhuMAB-β7 (RG7413)	<ul style="list-style-type: none"> Ulcerative colitis 		
Rontalizumab (Anti-IFN α , RG7415)	<ul style="list-style-type: none"> Systemic lupus erythematosus 		

METABOLISM

Molecule	Indication	Phase I	Phase II
Anti-oxLDL (RG7418)	<ul style="list-style-type: none"> Secondary prevention of cardiovascular events 		

NEUROSCIENCE

Molecule	Indication	Phase I	Phase II
Anti-Aβ (RG7412)	<ul style="list-style-type: none"> Alzheimer's Disease 		
Anti-Factor D (RG7417)	<ul style="list-style-type: none"> Geographic atrophy associated with AMD 		